×
Labcorp Receivables 2010-2024 | LH
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Labcorp receivables for the quarter ending September 30, 2024 were
$2.225B
, a
7.74% increase
year-over-year.
Labcorp receivables for 2023 were
$2.099B
, a
5.08% increase
from 2022.
Labcorp receivables for 2022 were
$1.997B
, a
32.94% decline
from 2021.
Labcorp receivables for 2021 were
$2.978B
, a
1.27% decline
from 2020.
View More
Labcorp Receivables 2010-2024 | LH
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Labcorp receivables for 2023 were
$2.099B
, a
5.08% increase
from 2022.
Labcorp receivables for 2022 were
$1.997B
, a
32.94% decline
from 2021.
Labcorp receivables for 2021 were
$2.978B
, a
1.27% decline
from 2020.
Related Stocks
Company Name
Market
Cap
McKesson (MCK)
$78.2B
Becton Dickinson (BDX)
$64.4B
Cardinal Health (CAH)
$28.6B
West Pharmaceutical Services (WST)
$22B
Cooper (COO)
$19.7B
Align Technology (ALGN)
$16.6B
Henry Schein (HSIC)
$9.3B
Merit Medical Systems (MMSI)
$6.1B
DENTSPLY SIRONA (XRAY)
$3.8B
CONMED (CNMD)
$2.2B
Patterson (PDCO)
$1.8B
STAAR Surgical (STAA)
$1.3B
Lifevantage (LFVN)
$170M
Pro-Dex (PDEX)
$147M